Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients

Cornelia Knaak, Friederike S Schuster, Peter Nyvlt, Patrick Heeren, Claudia Spies, Thomas Schenk, Paul La Rosée, Gritta Janka, Frank M Brunkhorst, Gunnar Lachmann, Cornelia Knaak, Friederike S Schuster, Peter Nyvlt, Patrick Heeren, Claudia Spies, Thomas Schenk, Paul La Rosée, Gritta Janka, Frank M Brunkhorst, Gunnar Lachmann

Abstract

Background: Ferritin is the major iron storage protein and an acute phase reactant. Hyperferritinemia is frequently seen in the critically ill where it has been hypothesized that not only underlying conditions but also factors such as transfusions, hemodialysis and extracorporeal life support (ECLS) lead to hyperferritinemia. This study aims to investigate the influence of transfusions, hemodialysis, and ECLS on hyperferritinemia in a multidisciplinary ICU cohort.

Methods: This is a post-hoc analysis of a retrospective observational study including patients aged ≥ 18 years who were admitted to at least one adult ICU between January 2006 and August 2018 with hyperferritinemia ≥ 500 μg/L and of ≥ 14 days between two ICU ferritin measurements. Patients with hemophagocytic lymphohistiocytosis (HLH) were excluded. To identify the influence of transfusions, hemodialysis, and ECLS on ferritin change, multivariable linear regression analysis with ferritin change between two measurements as dependent variable was performed.

Results: A total of 268 patients was analyzed. Median duration between measurements was 36 days (22-57). Over all patients, ferritin significantly increased between the first and last measurement (p = 0.006). Multivariable linear regression analysis showed no effect of transfusions, hemodialysis, or ECLS on ferritin change. Changes in aspartate aminotransferase (ASAT) and sequential organ failure assessment (SOFA) score were identified as influencing factors on ferritin change [unstandardized regression coefficient (B) = 2.6; (95% confidence interval (CI) 1.9, 3.3); p < 0.001 and B = 376.5; (95% CI 113.8, 639.1); p = 0.005, respectively]. Using the same model for subgroups of SOFA score, we found SOFA platelet count to be associated with ferritin change [B = 1729.3; (95% CI 466.8, 2991.9); p = 0.007]. No association of ferritin change and in-hospital mortality was seen in multivariable analysis.

Conclusions: The present study demonstrates that transfusions, hemodialysis, and ECLS had no influence on ferritin increases in critically ill patients. Hyperferritinemia appears to be less the result of iatrogenic influences in the ICU thereby underscoring its unskewed diagnostic value.

Trial registration: The study was registered with www.ClinicalTrials.gov (NCT02854943) on August 1, 2016.

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig 1. Consort diagram.
Fig 1. Consort diagram.
Fig 2. Distribution of ferritin values between…
Fig 2. Distribution of ferritin values between first and last measurement.
Median duration between two measurements was 36 (22–57) days. Boxplots show median with quartiles (25%, 75%). Whiskers below and above show minimum and maximum values, respectively. For visualization, y-axis is plotted in logarithmic scale.

References

    1. Fleming RE, Ponka P (2012) Iron overload in human disease. The New England journal of medicine 366 (4):348–359. doi: 10.1056/NEJMra1004967
    1. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM (2009) Ferritin for the clinician. Blood Rev 23 (3):95–104. doi: 10.1016/j.blre.2008.08.001
    1. Senjo H, Higuchi T, Okada S, Takahashi O (2018) Hyperferritinemia: causes and significance in a general hospital. Hematology 23 (10):817–822. doi: 10.1080/10245332.2018.1488569
    1. Cullis JO, Fitzsimons EJ, Griffiths WJ, Tsochatzis E, Thomas DW, British Society for H (2018) Investigation and management of a raised serum ferritin. Br J Haematol 181 (3):331–340. doi: 10.1111/bjh.15166
    1. Norring-Agerskov D, Bathum L, Pedersen OB, Abrahamsen B, Lauritzen JB, Jorgensen NR, et al. (2019) Biochemical markers of inflammation are associated with increased mortality in hip fracture patients: the Bispebjerg Hip Fracture Biobank. Aging clinical and experimental research 31 (12):1727–1734. doi: 10.1007/s40520-019-01140-7
    1. Grossekatthofer M, Guclu ED, Lawitschka A, Matthes-Martin S, Mann G, Minkov M, et al. (2013) Ferritin concentrations correlate to outcome of hematopoietic stem cell transplantation but do not serve as biomarker of graft-versus-host disease. Ann Hematol 92 (8):1121–1128. doi: 10.1007/s00277-013-1737-x
    1. Unal AU, Kostek O, Takir M, Caklili O, Uzunlulu M, Oguz A (2015) Prognosis of patients in a medical intensive care unit. North Clin Istanb 2 (3):189–195. doi: 10.14744/nci.2015.79188
    1. Lachmann G, Knaak C, Vorderwulbecke G, La Rosee P, Balzer F, Schenk T, et al. (2020) Hyperferritinemia in Critically Ill Patients. Critical care medicine 48 (4):459–465. doi: 10.1097/CCM.0000000000004131
    1. La Rosee P, Horne A, Hines M, von Bahr Greenwood T, Machowicz R, Berliner N, et al. (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133 (23):2465–2477. doi: 10.1182/blood.2018894618
    1. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48 (2):124–131. doi: 10.1002/pbc.21039
    1. Sackett K, Cunderlik M, Sahni N, Killeen AA, Olson AP (2016) Extreme Hyperferritinemia: Causes and Impact on Diagnostic Reasoning. Am J Clin Pathol 145 (5):646–650. doi: 10.1093/ajcp/aqw053
    1. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, et al. (2015) Marked hyperferritinemia does not predict for HLH in the adult population. Blood 125 (10):1548–1552. doi: 10.1182/blood-2014-10-602607
    1. Polaschegg HD (2009) Red blood cell damage from extracorporeal circulation in hemodialysis. Semin Dial 22 (5):524–531. doi: 10.1111/j.1525-139X.2009.00616.x
    1. Angeletti A, Zappulo F, Donadei C, Cappuccilli M, Di Certo G, Conte D, et al. (2020) Immunological Effects of a Single Hemodialysis Treatment. Medicina (Kaunas) 56 (2). doi: 10.3390/medicina56020071
    1. Murphy DA, Hockings LE, Andrews RK, Aubron C, Gardiner EE, Pellegrino VA, et al. (2015) Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev 29 (2):90–101. doi: 10.1016/j.tmrv.2014.12.001
    1. Millar JE, Fanning JP, McDonald CI, McAuley DF, Fraser JF (2016) The inflammatory response to extracorporeal membrane oxygenation (ECMO): a review of the pathophysiology. Crit Care 20 (1):387. doi: 10.1186/s13054-016-1570-4
    1. Knaak C, Nyvlt P, Schuster FS, Spies C, Heeren P, Schenk T, et al. (2020) Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care 24 (1):244. doi: 10.1186/s13054-020-02941-3
    1. Ho CH (1992) The effects of blood transfusion on serum ferritin, folic acid, and cobalamin levels. Transfusion 32 (8):764–765. doi: 10.1046/j.1537-2995.1992.32893032107.x
    1. Knaak C, Schuster FS, Spies C, Vorderwulbecke G, Nyvlt P, Schenk T, et al. (2020) Hemophagocytic Lymphohistiocytosis in Critically Ill Patients. Shock 53 (6):701–709. doi: 10.1097/SHK.0000000000001454
    1. Labor, Berlin (2020) Haptoglobin. . Accessed 12/10/2020 2020.
    1. Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E, et al. (2009) Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 114 (21):4632–4638. doi: 10.1182/blood-2009-02-203323
    1. Gao C, Li L, Chen B, Song H, Cheng J, Zhang X, et al. (2014) Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia. Patient Prefer Adherence 8:513–517. doi: 10.2147/PPA.S56238
    1. Froissart A, Rossi B, Ranque B, Jarrin I, Bergmann JF, Beaune S, et al. (2018) Effect of a Red Blood Cell Transfusion on Biological Markers Used to Determine the Cause of Anemia: A Prospective Study. Am J Med 131 (3):319–322. doi: 10.1016/j.amjmed.2017.10.005
    1. Boshuizen M, van Hezel ME, van Manen L, Straat M, Somsen YBO, Spoelstra-de Man AME, et al. (2019) The effect of red blood cell transfusion on iron metabolism in critically ill patients. Transfusion 59 (4):1196–1201. doi: 10.1111/trf.15127
    1. Mitchell O, Feldman DM, Diakow M, Sigal SH (2016) The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med 8:39–50. doi: 10.2147/HMER.S74612
    1. van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, et al. (2019) Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica 104 (2):e51–e53. doi: 10.3324/haematol.2018.196295
    1. Weinstein T, Chagnac A, Korzets A, Boaz M, Ori Y, Herman M, et al. (2000) Haemolysis in haemodialysis patients: evidence for impaired defence mechanisms against oxidative stress. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association—European Renal Association 15 (6):883–887. doi: 10.1093/ndt/15.6.883
    1. Tharmaraj D, Kerr PG (2017) Haemolysis in haemodialysis. Nephrology (Carlton) 22 (11):838–847. doi: 10.1111/nep.13119

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera